Contact Us at (201)-274-2504

International Scientific Conference
on Infantile Neuroaxonal Dystrophy (INAD)

and other types of PLA2G6-Associated Neurodegeneration (PLAN)

REGISTRATION NOW OPEN!

The INADcure Foundation is excited to announce the Inaugural International Scientific Conference on Infantile Neuroaxonal Dystrophy/PLAN to be held virtually November 10th & 11th, 2021.

For the first time ever, scientists and experts from around the globe will convene to share knowledge on Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-associated neurodegeneration (PLAN), present on the latest discoveries in INAD/PLAN research, network, and identify opportunities for collaboration. This conference will bring together academia, the pharmaceutical and biotech industries, government agencies, and key leaders from patient advocacy organizations to focus on new therapeutic solutions and innovations to address the needs of INAD patients.

To this aim, the conference will include an interactive roundtable discussion on the significance of shared mechanisms with other neurodegenerative diseases, including Parkinson’s, dementia with Lewy bodies, and various lysosomal storage disorders, and identify common therapeutic targets for drug development.

In order to foster university-industry-regulator collaboration, the conference will include dedicated time throughout the 2-day event for networking and idea exchange. Each presentation will also end with an opportunity for questions and dialogue to further promote interaction among participants.

Leveraging what is learned from this blend of scientists and experts, the INADcure Foundation, the only patient advocacy organization dedicated exclusively to advancing INAD research and supporting the INAD community worldwide, will develop a comprehensive and collaborative strategy to combat INAD. The conference will also serve as the kickoff to the INAD Collaborative Research Network, an initiative designed to create opportunities for data sharing and to foster academic-industry collaborations to accelerate therapeutic and translational research.